Scopus

China-US Research: Common Good Must Triumph Over Mutual Suspicion, Says New Report

Retrieved on: 
Wednesday, August 3, 2022
Communications, Environment, Sustainability, Research, Publishing, Science, Publishing, Public policy, Climate change, University, APRU, Publication, Woman, Association of Pacific Rim Universities, Education, Global health, Association, United, Knowledge, Ageing, Goal, Policy, Common, Research, City, Science, RELX, Solution, Health, Artificial intelligence, Â, Scopus, COVID, Leadership, Waste management, United Nations Sustainable Development Group, Esports, Elsevier, Population, Pharmaceutical industry, Renewable energy

US universities are being warned about the need to safeguard intellectual property against perceived conflicts of interest.

Key Points: 
  • US universities are being warned about the need to safeguard intellectual property against perceived conflicts of interest.
  • Yet, as a new report from APRU and Elsevier demonstrates, the world cannot afford a break between the two largest producers of published research.
  • The report For the Common Good: APRU and the China-US Research Landscape shows the importance of maintaining relationships that have been built over decades for the benefit of global society.
  • Elsevier is part of RELX , a global provider of information-based analytics and decision tools for professional and business customers.

Scopus BioPharma Announces $9.75 Million Private Placement Priced At-The-Market

Retrieved on: 
Monday, November 22, 2021
Aio Wireless, Therapure BioPharma Inc, Security (finance), Sale, Securities Act of 1933, Forward-looking statement, Acquisition, Company, Gene silencing, Galena Biopharma, Tumor microenvironment, SEC, U.S. Securities and Exchange Commission, Sirna, Scopus, Twitter, GLOBE, TLR, Venture round, RNA, TLR9, Immunotherapy

The offering is expected to close on or about November 22, 2021, subject to satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on or about November 22, 2021, subject to satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need.
  • Further, there can be no assurance that the Company will identify and/or consummate any transaction relating to any additional technologies.

Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity

Retrieved on: 
Friday, October 1, 2021
U.S. Securities and Exchange Commission, Galena Biopharma, United States Attorney, United States, Forward-looking statement, Therapure BioPharma Inc, Assistant United States Attorney, Nasdaq, Crime, RICO, Fraud, Scopus, GLOBE, Pharmaceutical industry, Private investigator

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: SCPS), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation.

Key Points: 
  • NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: SCPS), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation.
  • In the past several weeks, the shares of Scopus BioPharma have come under attack by abusive short sellers.
  • During this period, the short volume ratio has reached nearly 70% and over 25% of the companys market capitalization has been wiped out.
  • Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need.

Scopus BioPharma to Present at MicroCap Rodeo’s Fall Harvest Best Ideas Conference

Retrieved on: 
Friday, October 1, 2021
RNA, U.S. Securities and Exchange Commission, Scopus, TLR9, TLR, Immunotherapy, Twitter, Acquisition, Sutro Biopharma, Sirna, Duet, Forward-looking statement, Therapure BioPharma Inc, Tumor microenvironment, Gene silencing, Pharmaceutical industry

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it will be presenting at The MicroCap Rodeo’s Fall Harvest Best Ideas Conference, which is being held virtually from October 5th through 8th, 2021.

Key Points: 
  • Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need.
  • The companys lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment of multiple cancers.
  • In addition, the company is developing additional drug candidates that target the endocannabinoid system, including MRI-1867 for the treatment systemic sclerosis.
  • Further, there can be no assurance that the company will identify and/or consummate any transaction relating to any additional technologies.

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Retrieved on: 
Tuesday, September 28, 2021
RNA, U.S. Securities and Exchange Commission, Scopus, TLR9, TLR, Immunotherapy, Twitter, Acquisition, Sutro Biopharma, Sirna, Duet, Forward-looking statement, Therapure BioPharma Inc, Tumor microenvironment, Gene silencing, Pharmaceutical industry

Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need.

Key Points: 
  • Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need.
  • The companys lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment of multiple cancers.
  • In addition, the company is developing additional drug candidates that target the endocannabinoid system, including MRI-1867 for the treatment systemic sclerosis.
  • Further, there can be no assurance that the company will identify and/or consummate any transaction relating to any additional technologies.

Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders

Retrieved on: 
Tuesday, September 28, 2021
RNA, Annual, Delaware Court of Chancery, U.S. Securities and Exchange Commission, Annual general meeting, Annual Meetings of the International Monetary Fund and the World Bank Group, Scopus, TLR9, TLR, Immunotherapy, Twitter, Acquisition, Sutro Biopharma, Sirna, Delaware Court, Forward-looking statement, Therapure BioPharma Inc, Tumor microenvironment, Nasdaq, Gene silencing, GLOBE

in connection with pending claims brought by Dr. Laster in the Delaware Court of Chancery, the company intends to convene, and then immediately adjourn, the companys scheduled October 8, 2021 Annual Meeting of Stockholders (the Annual Meeting) such that the Annual Meeting will be held and the vote on the items of business to be considered at the Annual Meeting will be taken no earlier than 14 days after a decision on the merits or a final settlement between the parties.

Key Points: 
  • in connection with pending claims brought by Dr. Laster in the Delaware Court of Chancery, the company intends to convene, and then immediately adjourn, the companys scheduled October 8, 2021 Annual Meeting of Stockholders (the Annual Meeting) such that the Annual Meeting will be held and the vote on the items of business to be considered at the Annual Meeting will be taken no earlier than 14 days after a decision on the merits or a final settlement between the parties.
  • No business will be conducted at the October 8, 2021 Annual Meeting other than to adjourn the Annual Meeting to a later date.
  • The company will announce the date on which the adjourned Annual Meeting will be reconvened at the October 8, 2021 Annual Meeting.
  • The record date for the Annual Meeting will remain August 16, 2021.

Scopus BioPharma to Present at the Benzinga Healthcare Small Cap Conference

Retrieved on: 
Thursday, September 23, 2021
RNA, U.S. Securities and Exchange Commission, Scopus, TLR9, TLR, Immunotherapy, Twitter, Acquisition, Sutro Biopharma, Sirna, Duet, Forward-looking statement, Therapure BioPharma Inc, Tumor microenvironment, Gene silencing, Pharmaceutical industry

Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need.

Key Points: 
  • Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need.
  • The companys lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment of multiple cancers.
  • Receive updates by following Scopus BioPharma on Twitter here .
  • Further, there can be no assurance that the company will identify and/or consummate any transaction relating to any additional technologies.

Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Retrieved on: 
Wednesday, September 22, 2021
RNA, U.S. Securities and Exchange Commission, Scopus, TLR9, TLR, Immunotherapy, Twitter, Acquisition, Sutro Biopharma, Sirna, Duet, Forward-looking statement, Therapure BioPharma Inc, Tumor microenvironment, Gene silencing, Pharmaceutical industry

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society.

Key Points: 
  • Duet is also evaluating combination therapies with checkpoint inhibitors.
  • Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need.
  • The companys lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment of multiple cancers.
  • Further, there can be no assurance that the company will identify and/or consummate any transaction relating to any additional technologies.

Scopus BioPharma’s Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting

Retrieved on: 
Friday, September 3, 2021
Acquisition, Therapure BioPharma Inc, Twitter, U.S. Securities and Exchange Commission, Sirna, Duet, Forward-looking statement, TLR9, Gene silencing, Lymphatic system, Scopus, STAT3, Prostate, Otorhinolaryngology, Immunotherapy, Tumor microenvironment, Sutro Biopharma, RNA, TLR, Kidney

Current and potential indications for the Duet Platform include: B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, genitourinary (e.g., prostate, kidney and bladder) and head & neck cancers.

Key Points: 
  • Current and potential indications for the Duet Platform include: B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, genitourinary (e.g., prostate, kidney and bladder) and head & neck cancers.
  • Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need.
  • The companys lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment of multiple cancers.
  • Further, there can be no assurance that the company will identify and/or consummate any transaction relating to any additional technologies.

Scopus BioPharma Launches Duet Therapeutics

Retrieved on: 
Thursday, September 2, 2021
Acquisition, Therapure BioPharma Inc, Twitter, U.S. Securities and Exchange Commission, Sirna, Duet, Forward-looking statement, TLR9, Gene silencing, Scopus, STAT3, Immunotherapy, Tumor microenvironment, Sutro Biopharma, RNA, TLR, Vaccine

NEW YORK, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the launch of Duet Therapeutics.

Key Points: 
  • In 2022, Duet is targeting to file two INDs for DUET-02 in two separate indications: genitourinary and head & neck cancers.
  • Duet is also evaluating combination therapies with checkpoint inhibitors.
  • Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need.
  • Receive updates by following Scopus BioPharma on Twitter here .